2012 Update on diabetic kidney disease: The expanding spectrum, novel pathogenic insights and recent clinical trials

Minerva Medica

Volumn 103, Issue 4, 2012, Pages 219-234

  Fernandez Fernandez B ^a   Elewa, U ^a   Sanchez Nino M D ^b   Rojas Rivera, J E ^a   Martin Cleary, C ^a   Egido, J ^a,c,d   Ortiz, A ^a,c,d  

^a 28400 Madrid   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Section of Nephrology   (Spain)

Author keywords

Albuminuria; Atrasentan; Diabetic nephropathies

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; AVOSENTAN; BARDOXOLONE METHYL; CD74 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; PARICALCITOL; PENTOXIFYLLINE; PIRFENIDONE; PYRIDOXAMINE; RAMIPRIL; SPIRONOLACTONE; SULODEXIDE; TELMISARTAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VITAMIN D;

ALBUMINURIA; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; PATHOGENESIS; PODOCYTE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; KIDNEY FAILURE, CHRONIC; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; PODOCYTES; PROTEOMICS; RENAL AGENTS; RENIN-ANGIOTENSIN SYSTEM; REPRESSOR PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84867415218     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011;86:444-56.
2. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9.
3. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011;171:412-20.
4. Moreno JA, Sanchez-Nino MD, Sanz AB, Lassila M, Holthofer H, Blanco-Colio LM et al. A: A slit in podocyte death. Curr Med Chem 2008;15:1645-54.
5. Mandache E, Penescu M. Nanostructural features of diabetic podocytopathy. Rom J Morphol Embryol 2012;53:23-7.
6. Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M et al. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 2005;54:1487-96. (Pubitemid 40586681)
7. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010;33:1536-43.
8. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-7. (Pubitemid 37430080)
9. Packham DK, Ivory SE, Reutens AT, Wolfe R, Rohde R, Lambers HH et al. Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron Clin Pract 2011;118:c331-c8.
10. Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010;77:57-64.
11. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH et at. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007;18:1353-61. (Pubitemid 46536923)
12. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006;29:1560-6. (Pubitemid 44127581)
13. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de FM, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011;7:327-40.
14. Navarro-Gonzalez JF, Jarque A, Muros M, Mora C, Garcia J. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 2009;20:165-73.
15. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006;17:368-77.
16. Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009;4:62-70.
17. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011;13:160-6.
18. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65.
19. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90. (Pubitemid 36706063)
20. van der Kloet FM, Tempels FW, Ismail N, van der Heijden R, Kasper PT, Rojas-Cherto M et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 2012;8:109-19.
21. Sanchez-Nino MD, Benito-Martin A, Ortiz A. New paradigms in cell death in human diabetic nephropathy. Kidney Int 2010;78:737-44.
22. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011;60:2354-69.
23. Alkhalaf A, Zurbig P, Bakker SJ, Bilo HJ, Cerna M, Fischer C et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010;5.el3421.
24. Maahs DM, Siwy J, Argiles A, Cerna M, Delles C, Dominiczak AF et al. Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS One 2010;5.
25. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008;19:1283-90.
26. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006;55:2993-3003. (Pubitemid 44923635)
27. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, Yee B et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009;58:469-77.
28. Lindenmeyer MT, Rastaldi MP, Ikehata M, Neusser MA, Kretzler M, Cohen CD et al. Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol 2008;19:2225-36.
29. Sanchez-Nino MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 2009;20:353-62.
30. Sanchez-Nino MD, Sanz AB, Lorz C, Gnirke A, Rastaldi MP, Nair V et al. BASPl promotes apoptosis in diabetic nephropathy. J Am Soc Nephrol 2010;21:610-21.
31. Lorz C, Benito-Martin A, Boucherot A, Ucero AC, Rastaldi MP, Henger A et al. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 2008;19:904-14.
32. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M et al. NF-kappaB in renal inflammation. J Am Soc Nephrol 2010;21:1254-62.
33. Moreno JA, Izquierdo MC, Sanchez-Nino MD, Suarez-Alvarez B, Lopez-Larrea C, Jakubowski A et al. The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol 2011;22:1315-25.
34. Ortiz-Munoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 2010;21:763-72.
35. Sanz AB, Santamaría B, Ruiz-Ortega M, Egido J, Ortiz A. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008;19:1634-42.
36. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Investig Med 1997;45:50-6. (Pubitemid 127453337)
37. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005;54:2424-9. (Pubitemid 41134271)
38. Catalan MP, Santamaria B, Reyero A, Ortiz A, Egido J, Ortiz A. 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int 2005;68:1303-11. (Pubitemid 43246451)
39. Sanchez-Nino MD, Benito-Martin A, Goncalves S, Sanz AB, Ucero AC, Izquierdo MC et al. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm 2010.
40. Ortiz A, Bustos C, Alonso J, Alcazar R, Lopez-Armada MJ, Plaza JJ et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv Nephrol Necker Hosp 1995;24:53-77.
41. Ortiz A, Lorz C, Egido J. New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol 1999;12:150-8. (Pubitemid 29370822)
42. Sasaki S, Nishihira J, Ishibashi T, Yamasaki Y, Obikane K, Echigoya M et al. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int 2004;65:469-81. (Pubitemid 38130641)
43. Lorz C, Justo P, Sanz A, Subira D, Egido J, Ortiz A. Paracetamol-induced renal tubular injury: a role for ER stress. J Am Soc Nephrol 2004;15:380-9. (Pubitemid 38140778)
44. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000;403:98-103. (Pubitemid 30038529)
45. Brosius FC, III, Kaufman RJ. Is the ER stressed out in diabetic kidney disease? J Am Soc Nephrol 2008;19:2040-2.
46. Andersen S, Mischak H, Zurbig P, Parving HH, Rossing P. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010;11:29.
47. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl 1):S11-S63.
48. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-76.
49. Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med 2012;366:1319-27.
50. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247-51. (Pubitemid 24324966)
51. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
52. Ting RZ, Luk AO, Chan JC. Treatment and landmark clinical trials for renoprotection. Contrib Nephrol 2011;170:184-95.
53. Ingelfinger JR. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes. N Engl J Med 2011;364:970-1.
54. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62. (Pubitemid 23335891)
55. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
56. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-92.
57. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
58. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
59. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51. (Pubitemid 39447135)
60. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17.
61. Nelson RG, Turtle KR: Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors. Am J Kidney Dis 2010; 55:426-430
62. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of Perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM 2001;94:89-94. (Pubitemid 32175534)
63. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8. (Pubitemid 28275174)
64. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCUD Study Group. Lancet 1997;349:1787-92.
65. Bilous R, Chaturvedi N, Sjolie AK, Fuller J, Klein R, Orchard T et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-4.
66. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
67. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Barat A, Martin-Cleary C, Egido J. Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis? BMC Nephrol 2012;13:21.
68. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
69. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
70. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losarían in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46. (Pubitemid 351793017)
71. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T Combination treatment of angiotensinII receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24. (Pubitemid 36092015)
72. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney 2006;48:8-20.
73. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009;4:361-8.
74. Panesar M, Damodar A. Aliskiren combined with losaritan in diabetes and nephropathy. N Engl J Med 2008;359:1068-70.
75. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. [Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]. Ugeskr Laeger 2009;171:881-4.
76. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalemia and acute kidney injury: systematic review and meta-analysis. BMJ 2012;344.e42.
77. Parving HH, Brenner BM, McMurray JJ, de ZD, Haffner SM, Solomon SD et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using CardioRenal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012.
78. Cha DR, Kang YS, Han SY, Jee YH, Han KH, Kim HK et al. Role of aldosterone in diabetic nephropathy. Nephrology (Carlton) 2005;10(Suppl):S37-S9.
79. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24:2285-92. (Pubitemid 44611039)
80. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-51.
81. Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S. Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther 2012;34:1237-46.
82. de ZD, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-51.
83. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-36.
84. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-64.
85. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-35.
86. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-72.
87. Andress D, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan D. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 2012 [Epub ahead of print].
88. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011;22:1144-51.
89. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23:131-6.
90. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23:123-30.
91. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis 2011;58:729-36.
92. Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, Herrera H, Meneses B, Garcia J. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications 2011;25:314-9.
93. Turtle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686-90. (Pubitemid 43951160)
94. Sanaka T, Akizawa T, Koide K, Koshikawa S. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther Apher Dial 2004;8:232-40. (Pubitemid 38900430)
95. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 2011;74:537-45.
96. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010;59:85060.
97. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 2012;18:3396-406.
98. Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010;25:2850-65.
99. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, Vacheva P, Gracia O, Ibarz M et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012;302.F647-F57.
100. Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 2011;26:1797-802.
101. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:1070-8. (Pubitemid 26183140)
102. Ortiz A, Sanchez Nino MD, Rojas J, Egido J. Paricalcitol for reduction of albuminuria in diabetes. Lancet 2011;377:635-6.
103. Krairittichai U, Mahannopkul R, Bunnag S. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease. J Med Assoc Thai 2012;95(Suppl 3):S4l-S7.
104. Ritz E, Wenzel RR. Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel? J Am Soc Nephrol 2011;22:593-5.
105. Soma J, Sato K, Saito H, Tsuchiya Y. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006;21:2795-9. (Pubitemid 44542233)
106. Chen JL, Francis J: Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy. J Am Soc Nephrol 2012;23:6-8.
107. Li J, Wu HM, Zhang L, Zhu B, Dong BR. Heparin and related substances for preventing diabetic kidney disease. Cochrane Database Syst Rev 2010;CD005631.
108. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005;16:2119-26. (Pubitemid 41716443)
109. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin- converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 2006;26:562-70. (Pubitemid 46143878)
110. Shan D, Wu HM, Yuan QY, Li J, Zhou RL, Liu GJ. Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev 2012;2:CD0006800.
111. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T et al. Phase 1 study of antiCTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010;5:1420-8.